NAD+ Peptide Therapy: Hype, Science, and What $400 a Vial Actually Buys You
NAD+ biology is real, but the clinic vial is less proven than the marketing suggests. Here is what the evidence actually supports.
GHK-Cu has multiple clinical trials for hair. AHK-Cu has one lab study. Here's what the evidence says about each copper peptide.

NAD+ biology is real, but the clinic vial is less proven than the marketing suggests. Here is what the evidence actually supports.
Cortisone keeps failing chronic tendinopathy. Here is the BPC-157, TB-500, GHK-Cu, and Thymosin alpha-1 evidence — and where the human RCT gap actually is.
MK-677 raises growth hormone and IGF-1 like the marketing promises. Across 30 years and six clinical-trial indications, none of those biomarker wins translated into the outcomes humans actually wanted.
Why Hollywood prefers CJC-1295 paired with Ipamorelin over exogenous HGH — the mechanism, the cycle, the recomp timeline, and the honest risks behind the look.
Hexarelin hits harder; Ipamorelin holds steadier. The lean-mass evidence in healthy adults is thinner than either side admits.
Bryan Johnson's public peptide story is narrower than the internet claims. Here's what is documented, what is speculation, and what to copy safely.
A conservative guide to anti-aging peptides after menopause, focused on skin support, GH-axis caution, HRT context, and monitoring.
A conservative, evidence-tiered protocol for men over 40 considering peptides, with screening, legal status, monitoring, and stop rules.

A safety-first guide to seven muscle-building peptides bodybuilders discuss, the evidence behind them, and three high-risk compounds to avoid.
GHK-Cu has multiple clinical trials for hair.
AHK-Cu has one lab study. Here's what the evidence says about each copper peptide.
The goal isn’t to be comfortable with change — it’s to be comfortable with one small change, on a schedule, held for a year.
We’re recording with NotebookLM. Expect a deep-dive and a short-form version of each issue’s best essays, delivered to your favorite podcast app when we launch.